Published in:
01-04-2015 | short review
A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma
Authors:
Bahil Ghanim, MD, Mir Alireza Hoda, MD, Thomas Klikovits, MD, Balazs Dome, MD, PhD, Michael Grusch, PhD, Martin Filipits, PhD, Walter Klepetko, MD, Walter Berger, PhD, Balazs Hegedus, PhD
Published in:
memo - Magazine of European Medical Oncology
|
Issue 1/2015
Login to get access
Abstract
Malignant pleural mesothelioma (MPM) is a devastating and treatment-resistant disease. Currently, well-established prognostic and predictive biomarkers are rare in clinical practice, whereas there is a whole body of various MPM biomarker studies published in medical literature in the past decades. Besides well-established pathological parameters, including histological subtype, disease stage, or level of lymph node involvement, blood parameters and circulating proteins related to a proinflammatory phenotype are emerging as prognostic biomarkers. Here we provide an overview about the current status of prognostic and predictive biomarkers in MPM, with a strong emphasis on their applicability in clinical practice.